Ann: PAC Partners release a Research Report, page-40

First 40 Last

Share
Profile

Follow
Rajenp5

1,801 Posts.

5

25/06/17

21:44

Post #: 25480365
Share

Originally posted by sharks37 ↑

Rajen I will quote an excerpt from a post about market makers that FullMoonFever posted to the STT thread this weekend:

"The savvy long-term investors never chase stocks up. For the most part that is momentum players and daytraders where most of it or what follows is dumb money. Instead the long-term investors use a couple of simple strategies in order to position themselves. One is to find a stock no one immediately sees has huge potential and accumulate. Long-term investors are not interested in trading against the public mind or the dumb money. That's where the majority of the money can be made but even more can be made if the base of a stock is held extremely strong by investors. However the second is not to doubt the research which is the underlying basis for going long and holding."

Now, only time will tell whether STL proves to be profitable for the "savvy" long term investors already on board, but one thing for sure is that patience will be required - yes it would have been nice to see the SP in the 4's by now but a lot of these small cap stocks end up taking longer than expected to materialise their potential returns (if they do). I don't think anything is gained by impatience here either patience is backed by confidence in your own research of decisiveness is required to acknowledge your thesis was wrong and it's time to cut and run. Only you can decide which way to go.

Cheers, Sharks

Expand

If you read my last post you might get a sense that I have been grappling with more than just my losing investment in STL. Whatever gripes I might have had I have mostly put to bed thru my brief exchange with oxxa23. I am quite grateful that he has been considerate and empathic in engaging with me. His attitude impressed me enough to follow his example. I know he has much much more to lose than I have, even though my holding is nothing to be sneezed at. Cheers

STL Price at posting: 2.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

HotCopper Highlights: Your most watched stocks for Week 48, 2024

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

There are more pages in this discussion • 3 more messages in this thread...

First 40 Last

Add STL (ASX) to my watchlist

Ann: PAC Partners release a Research Report, page-40

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Resolute shares bounce back as second payment made to Mali government to secure workers' release

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Featured News